Profile data is unavailable for this security.
About the company
Viracta Therapeutics, Inc. is a clinical-stage precision oncology company focused on the treatment and prevention of virus-associated cancers, which impact patients worldwide. The Company’s lead product candidate is an all-oral combination therapy of its proprietary investigational drug, nanatinostat, and the antiviral agent valganciclovir (collectively, Nana-val). Nana-val is being evaluated in multiple ongoing clinical trials, including a pivotal, global, multicenter, open-label Phase II basket trial for the treatment of multiple subtypes of relapsed or refractory (R/R) Epstein-Barr virus-positive (EBV+) lymphoma (NAVAL-1), as well as a multinational, open-label Phase Ib/II clinical trial for the treatment of patients with recurrent or metastatic (R/M) EBV + nasopharyngeal carcinoma (NPC) and other advanced EBV + solid tumors. The Company is also pursuing the application of its Kick and Kill approach in other virus-related cancers.
- Revenue in USD (TTM)0.00
- Net income in USD-45.34m
- Incorporated1998
- Employees40.00
- LocationViracta Therapeutics Inc2533 S COAST HWY 101, SUITE 210CARDIFF BY THE SEA 92007United StatesUSA
- Phone+1 (858) 400-8470
- Fax+1 (650) 266-3501
- Websitehttps://www.viracta.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Nascent Biotech Inc | 0.00 | -1.92m | 8.08m | -- | -- | -- | -- | -- | -0.012 | -0.012 | 0.00 | -0.003 | 0.00 | -- | -- | -- | -1,256.81 | -708.50 | -- | -- | -- | -- | -- | -589.83 | -- | -- | -- | -- | -- | -- | 25.47 | -- | -- | -- |
Correlate Energy Corp | 5.65m | -34.51m | 8.24m | 19.00 | -- | -- | -- | 1.46 | -0.8359 | -0.8359 | 0.1457 | -0.0461 | 1.50 | -- | 11.12 | 297,377.40 | -915.61 | -315.47 | -- | -- | -6.45 | 15.42 | -610.79 | -201.03 | -- | -1.07 | -- | -- | 122.20 | 46.12 | -78.54 | -- | -- | -- |
Cannabis Bioscience Internatnl Hlgs Inc | 56.94m | 6.94m | 8.31m | 389.00 | 0.0015 | 0.0002 | 0.9003 | 0.1459 | 0.5328 | 0.5328 | 4.29 | 4.92 | 0.5917 | 62.81 | 1.45 | 146,384.30 | 7.83 | -- | 11.73 | -- | 31.96 | -- | 13.24 | -- | 0.6856 | 50.75 | 0.0631 | -- | 12.79 | -- | 177.84 | -- | -- | -- |
Monopar Therapeutics Inc | 0.00 | -7.12m | 8.34m | 10.00 | -- | 1.37 | -- | -- | -2.31 | -2.31 | 0.00 | 1.73 | 0.00 | -- | -- | 0.00 | -81.33 | -54.07 | -102.31 | -60.60 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 20.10 | -- | -- | -- |
Plus Therapeutics Inc (USA) | 5.51m | -13.23m | 8.37m | 20.00 | -- | -- | -- | 1.52 | -3.05 | -3.05 | 1.19 | -1.34 | 0.4336 | -- | -- | 275,450.00 | -104.14 | -59.18 | -- | -133.04 | -- | -- | -240.15 | -470.45 | -- | -4.17 | -- | -- | 2,093.30 | -5.89 | 34.32 | -- | 3.77 | -- |
ABVC Biopharma Inc | 136.40k | -11.37m | 8.51m | 16.00 | -- | 0.995 | -- | 62.35 | -1.78 | -1.78 | 0.0172 | 0.6882 | 0.0114 | -- | 0.4213 | 8,525.00 | -99.79 | -103.38 | -197.79 | -231.54 | -24.11 | 76.25 | -8,762.13 | -2,019.89 | -- | -2.50 | 0.1873 | -- | -84.28 | 85.39 | 35.97 | -- | -- | -- |
Cyclerion Therapeutics Inc | 0.00 | -10.47m | 8.54m | 1.00 | -- | 0.9023 | -- | -- | -4.26 | 1.27 | 0.00 | 3.49 | 0.00 | -- | -- | 0.00 | -103.82 | -72.70 | -150.23 | -86.96 | -- | -- | -- | -2,565.62 | -- | -- | 0.00 | -- | -100.00 | -- | 30.98 | -- | -- | -- |
BioCardia Inc | 428.00k | -8.56m | 8.54m | 16.00 | -- | -- | -- | 19.95 | -5.40 | -5.40 | 0.2636 | -0.9233 | 0.0923 | -- | 6.85 | 26,750.00 | -184.48 | -107.34 | -1,075.25 | -154.17 | -- | -- | -1,999.77 | -1,779.24 | -- | -- | -- | -- | -64.72 | -5.26 | 2.82 | -- | -28.89 | -- |
Viracta Therapeutics Inc | 0.00 | -45.34m | 8.79m | 40.00 | -- | -- | -- | -- | -1.16 | -1.16 | 0.00 | 0.0678 | 0.00 | -- | -- | 0.00 | -83.82 | -86.35 | -140.98 | -106.38 | -- | -- | -- | -11,853.94 | -- | -59.78 | 0.8753 | -- | -- | -- | -3.78 | -- | -- | -- |
Calidi Biotherapeutics Inc | 0.00 | -24.92m | 8.89m | 41.00 | -- | -- | -- | -- | -5.41 | -5.41 | 0.00 | -1.82 | 0.00 | -- | -- | 0.00 | -279.89 | -- | -- | -- | -- | -- | -- | -- | -- | -27.58 | -- | -- | -100.00 | -- | -14.90 | -- | -- | -- |
Oncotelic Therapeutics Inc | 70.00k | -1.24m | 8.94m | 22.00 | -- | 0.737 | -- | 127.69 | -0.0031 | -0.0031 | 0.0002 | 0.0299 | 0.0023 | -- | 3.69 | 3,181.82 | -5.02 | -25.03 | -11.26 | -48.76 | -- | -- | -2,147.66 | -1,692.93 | -- | -0.5167 | 0.5228 | -- | -- | -- | -255.12 | -- | -- | -- |
Cardio Diagnostics Holdings Inc | 39.14k | -8.77m | 9.22m | 7.00 | -- | 2.92 | -- | 235.51 | -0.4899 | -0.4899 | 0.0021 | 0.1319 | 0.0073 | -- | 9.13 | 5,591.43 | -163.16 | -- | -268.73 | -- | -- | -- | -22,414.13 | -- | -- | -9.32 | 0.0295 | -- | 1,696.84 | -- | -79.72 | -- | -- | -- |
Organovo Holdings Inc | 73.00k | -13.99m | 9.24m | 12.00 | -- | 1.30 | -- | 126.55 | -1.39 | -1.39 | 0.0069 | 0.4635 | 0.006 | -- | 0.7411 | 3,650.00 | -115.47 | -54.25 | -136.97 | -58.42 | 50.68 | -- | -19,160.27 | -1,890.16 | 3.38 | -- | 0.00 | -- | -70.54 | -48.78 | 15.00 | -- | -11.87 | -- |
Traws Pharma Inc | 226.00k | -137.05m | 9.24m | 16.00 | -- | -- | -- | 40.89 | -5.53 | -5.53 | 0.0102 | 0.241 | 0.0092 | -- | 12.91 | 14,125.00 | -557.63 | -63.43 | -896.39 | -85.72 | -- | -- | -60,641.15 | -3,257.92 | -- | -- | 0.00 | -- | 0.00 | -28.72 | 0.0844 | -- | -- | -- |
National Graphite Corp | 0.00 | -1.97m | 9.26m | 0.00 | -- | -- | -- | -- | -0.0221 | -0.0221 | 0.00 | -0.0193 | 0.00 | -- | -- | -- | -11,014.44 | -212.13 | -- | -6,295.18 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -1,432.70 | -- | -- | -- |
Avalo Therapeutics Inc | 807.00k | -36.22m | 9.36m | 19.00 | -- | -- | -- | 11.60 | -63.82 | -63.82 | 0.3347 | -2.08 | 0.0122 | -- | 20.96 | 42,473.68 | -54.66 | -99.64 | -529.15 | -154.42 | 64.19 | 84.69 | -4,488.60 | -613.58 | -- | -- | -- | -- | -89.34 | -22.83 | 24.28 | -- | -22.48 | -- |
Holder | Shares | % Held |
---|---|---|
BVF Partners LPas of 30 Jun 2024 | 3.61m | 9.20% |
Citadel Advisors LLCas of 30 Jun 2024 | 1.52m | 3.87% |
The Vanguard Group, Inc.as of 30 Jun 2024 | 1.15m | 2.94% |
Laurion Capital Management LPas of 30 Jun 2024 | 407.30k | 1.04% |
Aisling Capital Management LPas of 30 Jun 2024 | 288.57k | 0.74% |
Geode Capital Management LLCas of 30 Jun 2024 | 270.77k | 0.69% |
BlackRock Fund Advisorsas of 30 Jun 2024 | 269.96k | 0.69% |
Apo Asset Management GmbHas of 30 Sep 2023 | 252.15k | 0.64% |
Renaissance Technologies LLCas of 30 Jun 2024 | 217.70k | 0.55% |
Morgan Stanley Smith Barney LLC (Investment Management)as of 30 Jun 2024 | 133.69k | 0.34% |